Effect of Hepatic Impairment on LDE225..
Completed · Phase 1
Conditions studied: Normal Hepatic Function, Impaired Hepatic Function
In brief
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
Key facts
- Study ID
- NCT01764776
- Run by
- Novartis Pharmaceuticals
- People needed
- 33
- Starts
- 2013-03-01
- Expected to finish
- 2015-03-01
- Last updated by the study team
- 2020-12-19
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- University of Miami Div. of Clinical Pharmacology — Miami, Florida, United States
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Sofia, Bulgaria
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Tel Aviv, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.